Diclofenac/hyaluronan topical - Vectura

Drug Profile

Diclofenac/hyaluronan topical - Vectura

Alternative Names: HYAL CT-1101; Solaraze

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SkyePharma PLC
  • Developer SkyePharma PLC; Vectura
  • Class Glycosaminoglycans; Nonsteroidal anti-inflammatories; Phenylacetates
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis
  • Discontinued Basal cell cancer

Most Recent Events

  • 31 Oct 2013 Generic equivalent approved in USA
  • 05 Dec 2011 Launched for Actinic keratosis in Spain (Topical)
  • 21 Feb 2008 Bradley Pharmaceuticals has been acquired by Nycomed US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top